SEOUL, South Korea, Feb. 24, 2026 — Medical device company Won BioGen, led by CEO Kim Won-il, is increasing the pace of its global market growth, driven by its sophisticated moist wound care technology and hydrocolloid-based products.
The company’s flagship product, Therasorb, is a polyurethane foam dressing designed to both preserve a moist environment and provide high absorption. This dual action encourages fast wound healing and prevents scab formation. The product has recently earned recognition in the medical community for its use across a range of clinical applications, such as burns, pressure ulcers, surgical wounds, donor sites, and diabetic foot ulcers.
Renoderm, Won BioGen’s hydrocolloid dressing brand, creates an ideal moist setting for skin repair by absorbing wound fluid and clearing away dead tissue. Praised for its clinically validated technology, it is commonly used for everything from small wounds to care after laser treatments. Both the Therasorb and Renoderm medical devices are on track to receive CE MDR certification in 2026. The company also offers Remscar, a scar management product in silicone gel and sheet forms, used for treating hypertrophic scars and keloids caused by surgery, burns, or trauma.
A key competitive advantage for Won BioGen is its successful extension of medical-grade hydrocolloid technology into the acne spot patch sector. These patches are produced using the same stringent quality control and manufacturing standards applied to clinical hydrocolloid dressings. As a result, Won BioGen operates as a major exporter of acne spot patches, primarily manufacturing products for leading brands in Japan and China through OEM and ODM agreements. The company has recently intensified its sales and marketing efforts to enter the North American and European markets.
To boost its international profile, Won BioGen is also actively engaging in exhibition marketing. The company displayed its foam dressings, hydrocolloid dressings, silicone scar products, and medical-grade skincare items at the WHX, Medica, and Cosmoprof trade shows, where they were met with favorable feedback. Significant interest was shown at the WHX Dubai and MEDICA exhibitions, where the company conducted numerous consultations with potential buyers from the Middle East, Europe, and Asia, indicating strong potential for new partnerships.
Looking ahead, the company intends to host booths under the Medisorb brand at the forthcoming Cosmoprof Cosmetics Exhibition in Bologna, Italy, and at Dubai Beauty World later this year. At these events, it will present its MD Cream medical device, skincare cosmetics, and spot patch products, while continuing export discussions with both B2C and B2B buyers.
A representative from Won BioGen stated that the company is enhancing its global market position by integrating its clinically established wound care expertise with rapidly growing hydrocolloid applications.
“By utilizing our proficiency in medical device production and a broadened ODM and OEM partnership approach, our goal is to establish ourselves as a leading global provider of next-generation wound care solutions,” the official concluded.
Website: